ClinicalTrials.gg
CompletedNCT07382180TIR-REALUpdated Feb 3, 2026

Real-World Tirzepatide Therapy in Post-Bariatric Weight Regain and Preoperative Obesity Patients

An observational study in Obesity & Overweight, Weight Regain and Obesity, Morbid, sponsored by Azienda Sanitaria Locale Napoli 2 Nord. Completed at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-03.

Primary conditionObesity, MorbidRegistry: ObesityReclassifiedWhy we changed it
Registry
Obesity — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity, Morbid
Why
  1. The study's listed conditions name Obesity, Morbid, a narrower term within Obesity.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Azienda Sanitaria Locale Napoli 2 Nord · Observational

How we know · 2 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
254
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Obesity, Morbid with a site in Italy — 11 open to participants now, 12 under way, none of them phase 3. Obesity, Morbid · Italy.

Enrollment
11th of 29
254 · median 180
Started
2025
with 1 other
Observational
29 of 54
3 open now
Registered
54th of 54
by date
Lead sponsor
3 of 54
Azienda Sanitaria Locale Napoli 2 Nord

Among the 54 studies in Obesity, Morbid with a site in Italy, this one is the 11th largest by enrollment of the 29 observational ones that give a count, is one of 2 that started in 2025, is one of 29 observational ones, and was the 54th registered.

Obesity, Morbid

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

Browse Obesity, Morbid studies →

Open to participants now

11 of the 54 studies in Obesity, Morbid with a site in Italy are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Obesity, Morbid with a site in Italy, or all of them as a file.
02

Study summary

This multicenter retrospective observational study evaluates the real-world use of tirzepatide in adult patients with post-bariatric weight regain and in patients with obesity undergoing preoperative management. The study analyzes changes in body weight and metabolic parameters, as well as treatment tolerability and safety, during routine clinical care. No experimental interventions are performed, and all patients receive tirzepatide as part of standard medical practice.

Read the detailed description

Obesity is a chronic and progressive disease that often requires long-term management. Although bariatric surgery is an effective treatment for severe obesity, a significant proportion of patients experience weight regain several years after surgery. In addition, many patients with obesity require medical treatment before surgery to reduce surgical risk and improve perioperative outcomes. In both situations, there is a growing need for effective and well-tolerated pharmacological therapies that can be integrated into routine clinical care.

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that has demonstrated significant effects on body weight reduction and metabolic control. While its efficacy has been established in randomized clinical trials, data on its use in real-world clinical practice, particularly in post-bariatric patients with weight regain and in patients undergoing preoperative obesity management, are still limited.

This multicenter observational cohort study evaluates the real-world use of tirzepatide in adult patients managed within routine bariatric and metabolic care pathways. The study includes two patient populations: individuals with clinically significant weight regain after sleeve gastrectomy and patients with obesity treated with tirzepatide as part of preoperative medical optimization before planned surgical intervention. All patients receive tirzepatide according to standard clinical practice, without any experimental procedures or protocol-mandated treatment changes.

Clinical, anthropometric, and metabolic data are collected at baseline and during scheduled follow-up visits, in accordance with routine care. The primary objective is to assess changes in body weight over time. Secondary objectives include evaluation of metabolic parameters, treatment tolerability, and the occurrence of adverse events. Safety data are collected as part of standard clinical monitoring.

By analyzing outcomes in a real-world setting, this study aims to provide clinically meaningful evidence on the effectiveness and safety of tirzepatide outside of controlled trial environments. The results are intended to support clinicians in decision-making for the management of obesity in complex clinical scenarios, such as post-bariatric weight regain and preoperative optimization, and to better define the role of pharmacological therapy as part of an integrated, long-term obesity care strategy.

03

Conditions studied

  • Obesity & Overweight
  • Weight Regain
  • Obesity, Morbid

Browse trials for

Keywords

  • Obesity
  • Weight Regain
  • Obesity, Morbid
04

In context

Obesity, Morbid Reclassified

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

This study's enrollment of 254 is above the median of 80 across 311 observational studies indexed under Obesity, Morbid.

Browse Obesity, Morbid studies →

Lead sponsor

Azienda Sanitaria Locale Napoli 2 Nord is the lead sponsor of 16 studies on the registry; 3 are open to participants now.

Compared within Obesity, Morbid, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Obesity. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of adult patients with obesity managed within established bariatric and metabolic care pathways at participating referral centers. Participants are selected from individuals who initiate tirzepatide therapy as part of routine clinical practice, either for medical optimization prior to planned bariatric surgery or for the management of clinically significant weight regain following prior sleeve gastrectomy.

All participants receive standard multidisciplinary care, including medical, nutritional, and metabolic evaluation, and are followed longitudinally through scheduled outpatient visits. The study population reflects a real-world clinical setting and includes patients with a broad range of obesity-related metabolic profiles, representative of routine bariatric practice.

Eligibility criteria

nclusion Criteria

  • Adult patients aged 18 years or older.
  • Diagnosis of obesity, defined according to standard clinical criteria, managed within a bariatric and metabolic care pathway.
  • Initiation of tirzepatide therapy at a starting dose of 5 mg as part of routine clinical practice.
  • Allocation to one of the following clinical cohorts:
  • Patients with prior sleeve gastrectomy and weight regain, defined as a ≥25% increase in body weight relative to the postoperative nadir weight, with a minimum interval of 36 months from surgery; or
  • Patients with obesity undergoing preoperative medical optimization prior to planned bariatric surgery.
  • Availability of complete baseline clinical and anthropometric data at treatment initiation.
  • Planned clinical follow-up for at least 6 months after initiation of tirzepatide therapy.
  • Ability to provide written for the use of clinical data for research purposes, according to local regulations.

Exclusion Criteria

  • Age younger than 18 years.
  • Prior bariatric procedures other than sleeve gastrectomy (for the weight regain cohort).
  • Current or previous treatment with tirzepatide before study enrollment.
  • Use of other anti-obesity pharmacological agents during the observation period.
  • to tirzepatide therapy according to the approved product label.
  • Pregnancy or breastfeeding at the time of treatment initiation or during follow-up.
  • Presence of severe medical, psychiatric, or cognitive conditions that, in the investigator's judgment, could interfere with adherence to treatment or follow-up assessments.
  • Incomplete baseline data or anticipated inability to complete the planned 6-month follow-up.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
254 participants (actual)
Patient registry
No

Groups and cohorts

  • Post-Bariatric Weight Regain

    Adult patients with a history of sleeve gastrectomy who developed clinically significant weight regain, defined as an increase of at least 25% from the postoperative nadir weight, and who were treated with tirzepatide as part of routine clinical care.

    Drug: Tirzepatide is administered as part of routine clinical care for obesity management, according to standard prescribing practices. Dosing and treatment duration are determined by the treating physician

  • Preoperative Obesity Management

    Adult patients with obesity receiving tirzepatide as part of preoperative medical optimization before planned bariatric or metabolic surgery, managed according to standard clinical practice.

    Drug: Tirzepatide is administered as part of routine clinical care for obesity management, according to standard prescribing practices. Dosing and treatment duration are determined by the treating physician

Interventions

  • DrugTirzepatide is administered as part of routine clinical care for obesity management, according to standard prescribing practices. Dosing and treatment duration are determined by the treating physician

    This study is conducted as a non-interventional, investigator-initiated observational study using data collected during routine clinical practice. No randomization, blinding, or protocol-mandated procedures are applied. Treatment decisions, follow-up schedules, and clinical assessments are determined solely by the treating physicians according to standard care. Data are collected retrospectively and prospectively from clinical records and routine follow-up visits. The study does not alter patient management and does not involve additional risks beyond usual clinical practice.

This study also gives TirzepatideStudies of TirzepatideTirzepatide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

07

What researchers measure

Primary outcomes

  1. Percentage Total Body Weight Loss (%TBWL)

    Percentage total body weight loss (%TBWL) was calculated as the percentage change in body weight from baseline to 6 months after initiation of tirzepatide therapy. Baseline body weight was defined as the body weight recorded at the start of treatment. Body weight measurements were obtained during scheduled outpatient visits using calibrated clinic scales, with participants wearing light clothing and no shoes. %TBWL was calculated using the following formula: \[(baseline body weight - follow-up body weight) / baseline body weight\] × 100. This outcome measure was selected as a standardized and clinically meaningful indicator of treatment effectiveness in obesity management, allowing comparison of weight reduction across patients with different baseline body weights and clinical indications.

    Time frame: From baseline (initiation of tirzepatide therapy) to 6 months of treatment

Secondary outcomes

  1. Change in Body Mass Index (BMI)

    Change in body mass index (BMI) from baseline to 6 months after initiation of tirzepatide therapy. BMI was calculated as body weight in kilograms divided by height in meters squared (kg/m²). Baseline BMI was defined as the value recorded at treatment initiation. Body weight and height were measured during outpatient visits using calibrated clinical equipment.

    Time frame: From baseline (initiation of tirzepatide therapy) to 6 months of treatment

  2. Safety and Tolerability of Tirzepatide

    Incidence and type of treatment-emergent adverse events during tirzepatide therapy, including gastrointestinal symptoms and treatment discontinuation due to adverse effects. Adverse events were collected through clinical visits and review of medical records and were classified according to routine clinical practice.

    Time frame: From baseline (initiation of tirzepatide therapy) to 6 months of treatment

  3. Change in Mood Status

    Change from baseline to 6 months in self-reported mood status, assessed during routine outpatient visits using the Patient Global Mood Assessment (PGMA), a standardized, non-diagnostic patient-reported outcome measure evaluating overall mood and emotional well-being. The Patient Global Mood Assessment (PGMA) is scored on a 7-point Likert scale, ranging from -3 (marked worsening of mood) to +3 (marked improvement of mood), with 0 indicating no change compared with baseline. Higher scores indicate improvement in mood and emotional well-being, while lower scores indicate worsening.

    Time frame: From baseline (initiation of tirzepatide therapy) to 6 months of treatment

08

Study locations

1 site
  • Head of bariatric surgery
    Naples, 80131, Italy
09

References and documents

Individual participant data

Plan to share: No — This is an observational real-world study based on data collected during routine clinical care. Individual participant data are derived from medical records and are subject to data protection and privacy regulations. No formal plan for sharing individual participant data has been established, as data analyses are conducted on de-identified, aggregated datasets to ensure confidentiality and regulatory compliance.

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2025 to primary completion in Jan 2026, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2026
First posted
Feb 2, 2026
StartActual
Feb 1, 2025
Primary completionActual
Jan 18, 2026
CompletionActual
Jan 18, 2026
Last update
Feb 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07382180
Lead sponsor
Azienda Sanitaria Locale Napoli 2 Nord
Responsible party
Francesco Pizza (surgeon, Azienda Sanitaria Locale Napoli 2 Nord) — Principal investigator
First posted
Feb 2, 2026
Start date
Feb 1, 2025
Primary completion
Jan 18, 2026
Completion
Jan 18, 2026
Last update
Feb 3, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion